KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...
The Floaty Zone on MSN

i Pretended to be NOOB in The Strongest Battlegrounds.. (ROBLOX)

Pretended to be NOOB in The Strongest Battlegrounds. I went undercover and disguised myself as a noob and trolled everyone in ...